Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT)

40.58
Delayed Data
As of Sep 22
 +3.61 / +9.76%
Today’s Change
5.00
Today|||52-Week Range
51.90
+623.35%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$82.3M

Company Description

Opiant Pharmaceuticals, Inc. is a biopharmaceutical company, which develops pharmaceutical solutions for common addictions and related disorders. The company focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Contact Information

Opiant Pharmaceuticals, Inc.
201 Santa Monica Boulevard
Santa Monica California 90401
P:(310) 598-5410
Investor Relations:
442036178728

Employees

Shareholders

Individual stakeholders8.58%
Mutual fund holders1.33%
Other institutional--

Top Executives

Roger CrystalPresident, CEO, Director & Head-Media Relations
David D. O'TooleChief Financial Officer
Phil R. SkolnickChief Scientific Officer
Kevin Andrew PollackSecretary, Treasurer & Director
Arvind AgrawalExecutive Vice President-Medical Affairs